Aurobindo Pharma to acquire some Sandoz products

Novartis is to sell around 300 of Sandoz’s US dermatology and generic oral solid products to the Indian pharma company Aurobindo, who will also acquire additional development projects, Sandoz’ dermatology development centre, and five manufacturing facilities in the US. Novartis will receive a cash sum of £900m and potential earnings of £100m from sales.
Richard Francis, Sandoz CEO, said: “Sharpening our portfolio focus in the US allows us to devote more time and resources toward our strategy of bringing complex generics, value-added medicines and biosimilars to patients, creating higher value and opening up access to important medicines where alternatives are truly needed.”